INSIDE THE LAB / ABOUT
We Have No Lab. We Just Read Everyone Else's.
How Magnifico Lab Peptides works, what the name actually means, and the editorial rules that govern every page on this site.
What this site is
Magnifico Lab Peptides is a reporting desk that reads the published research literature on a small set of peptides and translates it into plain, accurate language. The name is a nod to the site's method, not a claim about a facility — we do not run a laboratory, we do not conduct experiments, and we do not manufacture, stock or sell any compound. Every finding on this site traces back to a specific published study: an in vitro assay, an animal model, or a human trial. We name which one, every time, because the difference between a mouse result and a human result is not a footnote — it's the whole story.
How we read a study
Our method borrows something from science journalism and something from peer review. For every claim, we ask three questions before it goes on the page: What was actually tested — a cell line, an animal, or a person? What was the study design — an open-label pilot or a randomized, controlled trial? And what did the result actually show, including when it didn't clear the bar the researchers set for it? Ipamorelin's one human trial is a good example — the numbers moved in the hoped-for direction, but not by a statistically significant margin, and we report that plainly rather than rounding it up to a success [3]. That third question — reporting negative and null findings honestly — is where a lot of secondary peptide coverage online quietly fails, and it's the discipline this site tries hardest to hold.
What this site does not do
This site does not recommend a dose for any person, does not offer medical advice, and does not tell anyone what to buy or where. It does not evaluate research-chemical suppliers, verify product purity, or facilitate a purchase of any kind. Where community reports of real-world experience are included, they are always labeled as anecdotal — never presented as clinical fact, and never paired with a specific dose. Where a compound's evidence is thin or entirely preclinical, as with KPV and MOTS-c, this site says so directly rather than papering over the gap with confident-sounding language borrowed from a more advanced compound.
Sourcing and corrections
Every citation on this site links to a peer-reviewed journal article, a clinical-reference source, or a primary trial registration, listed in full on the references page. We re-verify identifiers like DOIs and PMIDs against their primary sources rather than trusting secondary web aggregators — a habit that matters more than it sounds, since misattributed identifiers are a documented, recurring problem in online peptide coverage. If a study we've cited is corrected, retracted, or superseded, our aim is to update the relevant page rather than let outdated claims sit indefinitely.
Who this is for
This site is written for the reader who wants to understand what the research literature actually says about ipamorelin, KPV, MOTS-c and tirzepatide — not a marketing summary of it. If that describes you, start with what's inside the lab, or jump straight to a side-by-side comparison of all four compounds.